Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Feb 24;24(1):260.
doi: 10.1186/s12885-024-11987-3.

Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial

Laura Iisager  1 , Johanne Ahrenfeldt  1 , Frede Donskov  2   3 , Börje Ljungberg  4 , Axel Bex  5 , Lars Lund  6 , Iben Lyskjær #  1 , Niels Fristrup #  7
Affiliations
Randomized Controlled Trial

Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial

Laura Iisager et al. BMC Cancer. .

Abstract

Background: Primary tumor removal by cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma patients has been investigated in the context of various treatment regimens. Two randomized controlled trials investigated the role and timing of cytoreductive nephrectomy in the era of targeted therapy and demonstrated that upfront nephrectomy should no longer be performed when patients require systemic therapy. Superiority of checkpoint immunotherapy agents has led to a paradigm change from targeted therapies to immunotherapy-based first-line treatment in patients with primary metastatic disease; thus, deferred cytoreductive nephrectomy needs to be verified in the immunotherapy setting. Furthermore, a need exists for personalizing treatment choices for the individual patient to avoid unnecessary overtreatment.

Methods/design: To explore the impact of cytoreductive nephrectomy in this patient group receiving checkpoint immunotherapy, we initiated a randomized, controlled trial comparing deferred cytoreductive nephrectomy with no surgery. The trial integrates a comprehensive translational research program with specimen sampling for biomarker analysis.

Discussion: The trial aims to show that deferred cytoreductive nephrectomy improves overall survival in patients with synchronous metastatic renal cell carcinoma, and furthermore, to identify relevant biomarkers for personalized renal cancer management.

Trial registration: ClinicalTrials.gov NCT03977571 June 6, 2019.

Keywords: Biomarkers; Deferred cytoreductive nephrectomy; Immunotherapy; Synchronous metastatic renal cell carcinoma; Translational research.

PubMed Disclaimer

Conflict of interest statement

NF has performed consultancy for Pfizer, Eisai, MSD, BMS, and has received speaker honoraria from AstraZeneca, BMS, MSD. BL: Company speaker: Novartis, IPSEN, BMS; Company consultant: Janssen, Ipsen, MSD; Trial participation: Jenssen—Astellas – Medivation. AB: grants from Pfizer and steering committee membership of Roche and BMS, consultancy for IPSEN. The other authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Study design. Arm A: Deferred CN followed by nivolumab or TKI-IO therapy. Arm B: No surgery, nivolumab or TKI-IO therapy. Arm C: Patients not eligible for randomization into Arm A or B. CN: Cytoreductive Nephrectomy; IO: Immunotherapy; mRCC: metastatic Renal Cell Carcinoma; Nivo: Nivolumab; TKI: Tyrosine Kinase Inhibitor. Generated with BioRender.com
See this image and copyright information in PMC

References

    1. Kammerer-Jacquet SF, Brunot A, Pladys A, Bouzille G, Dagher J, Medane S, et al. Synchronous metastatic clear-cell renal cell carcinoma: a distinct morphologic, immunohistochemical, and molecular phenotype. Clin Genitourin Cancer. 2017;15(1):e1–e7. doi: 10.1016/j.clgc.2016.06.007. - DOI - PubMed
    1. Donskov F, Xie W, Overby A, Wells JC, Fraccon AP, Sacco CS, et al. Synchronous versus metachronous metastatic disease: impact of time to metastasis on patient outcome-results from the international metastatic renal cell carcinoma database consortium. Eur Urol Oncol. 2020;3(4):530–539. doi: 10.1016/j.euo.2020.01.001. - DOI - PubMed
    1. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–148. doi: 10.1016/S1470-2045(12)70559-4. - DOI - PMC - PubMed
    1. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–366. doi: 10.1056/NEJMra1601333. - DOI - PubMed
    1. Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, et al. Updated European association of urology guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma. Eur Urol. 2018;74(6):805–809. doi: 10.1016/j.eururo.2018.08.008. - DOI - PubMed

Publication types

MeSH terms

Associated data